Athens-listed Lavipharm sells Hitex SAS

Athens-listed company Lavipharm announced on Tuesday that France’s Laboratoires Lavipharm SA, in which the Greek company holds a 45 percent stake, sold and transferred Hitex SAS, a 100 percent subsidiary, to French companies Fiag Holding, Codif Recherche & Nature and Robertet for 3,127,000 euros on Monday.

This transaction is expected to have a favorable impact on Lavipharm’s financial results up to December 31, 2013.

Hitex is active in the domain of research and development in supercritical fluid technologies.

Subscribe to our Newsletters

Enter your information below to receive our weekly newsletters with the latest insights, opinion pieces and current events straight to your inbox.

By signing up you are agreeing to our Terms of Service and Privacy Policy.